[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.121.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 5, 2005

Tirofiban Plus Sirolimus-Eluting Stent vs Abciximab Plus Bare-Metal Stent—Reply

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;294(13):1616-1618. doi:10.1001/jama.294.13.1617-b

In Reply: We agree with some of the comments raised by Dr Osman and colleagues, as we noted in the discussion of the limitations of our study. Among available glycoprotein IIb/IIIa inhibitors, Abciximab is the agent of choice in the context of primary intervention. When administered in the catheterization laboratory, abciximab, which provides rapid and complete antiplatelet effect, has been shown to be superior to tirofiban when administered as a 10-μg/kg bolus.1 When tirofiban is administered at this dose, the level of platelet inhibition reached after 10 to 15 minutes is suboptimal compared to that achieved using abciximab.

First Page Preview View Large
First page PDF preview
First page PDF preview
×